Sk Biopharmaceuticals Co Ltd (326030) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Sk Biopharmaceuticals Co Ltd KRW 83,490, price KRW 75,900, upside +10.0%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sk Biopharmaceuticals Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication.
Show more
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Stock analysis
Sk Biopharmaceuticals Co Ltd (326030) currently trades at 75,900 KRW, while our model-based Fair Value estimate is 83,490 KRW, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 158,371 KRW per share, and 8 of the 24 models we run sit above the 75,900 KRW price.
Bear case: the Economic Profit group reads lowest at 37,957 KRW, and 16 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 48,394 KRW (bear) to 175,949 KRW (bull), the price of 75,900 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sk Biopharmaceuticals Co Ltd reported revenue of 707B KRW in FY2025 versus 419B KRW in FY2021, a compound +14.0%/yr. Reported net income was 267B KRW in FY2025, compounding +42.4%/yr from FY2021.
Key figures
Market cap 6.5T KRW (≈ $4.5B) · P/S ratio 8.73 · Net margin 37.8% · Return on equity 44.2% · Return on assets (EBIT) 3.2% · Operating margin 39.4% · Revenue (TTM) 790B KRW · Revenue growth (YoY) +57.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 10%, 326030 screens cheaper than that median.
Fair Value models
Bear 48,394 KRWFair Value 83,490 KRWBull 175,949 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+29.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.1%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.7%
’16
’17
’19
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+32.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−921% → 29%
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +15.9% a year for the price and +16.0% for the forecasts.
Compare Sk Biopharmaceuticals Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+10% · Top 25%
Profitability
Return on equity (TTM)44% · Top 25%
Return on assets14% · Top 25%
Net margin (TTM)44% · Top 25%
Operating margin (TTM)39% · Top 25%
Growth and dividend
Revenue growth58% · Top 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sk Biopharmaceuticals Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/326030
Frequently asked questions
Is Sk Biopharmaceuticals Co Ltd (326030) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 83,490 KRW versus a price of 75,900 KRW, about +10% upside (undervalued).
What is the fair value of 326030?
Our model-based fair value for Sk Biopharmaceuticals Co Ltd is 83,490 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 75,900 KRW.
What is the quality score of 326030?
Sk Biopharmaceuticals Co Ltd has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sk Biopharmaceuticals Co Ltd (326030)?
Our model-based price target is the fair value of 83,490 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 48,394 KRW, optimistic scenario 175,949 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Sk Biopharmaceuticals Co Ltd stock forecast for 2026?
Our models put fair value at 83,490 KRW, about +10% upside versus a price of 75,900 KRW (undervalued). Cautious scenario 48,394 KRW, optimistic scenario 175,949 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Sk Biopharmaceuticals Co Ltd (326030)?
Sk Biopharmaceuticals Co Ltd reported trailing-twelve-month revenue of about 790B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into Sk Biopharmaceuticals Co Ltd (326030)?
For today's price to be fair in a discounted-cash-flow model, Sk Biopharmaceuticals Co Ltd would have to grow free cash flow by +18.3 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +93.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 326030 use?
Our models discount Sk Biopharmaceuticals Co Ltd at 8.5 %: a base by market capitalisation (mega), damped by beta 0.70, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sk Biopharmaceuticals Co Ltd that is +18.3 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Sk Biopharmaceuticals Co Ltd (326030) delivered so far?
Over the past 5 years revenue at Sk Biopharmaceuticals Co Ltd grew +93.6 % a year. The price currently implies +18.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sk Biopharmaceuticals Co Ltd (326030) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Sk Biopharmaceuticals Co Ltd (+18.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sk Biopharmaceuticals Co Ltd (326030)?
The free-cash-flow yield on the price is 2.47 %: that much free cash flow Sk Biopharmaceuticals Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sk Biopharmaceuticals Co Ltd (326030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sk Biopharmaceuticals Co Ltd it is 83,490 KRW per share (as of Sep 24, 2026), against a price of 75,900 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Sk Biopharmaceuticals Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 326030 trades below its calculated fair value: price 75,900 KRW, fair value 83,490 KRW, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 326030?
No. The price is what the market pays today (75,900 KRW); the fair value is what the company's own numbers justify (83,490 KRW). For Sk Biopharmaceuticals Co Ltd the two are 7,590 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Sk Biopharmaceuticals Co Ltd worth?
The market values Sk Biopharmaceuticals Co Ltd at about 6.5T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 75,900 KRW; our models calculate a fair value of 83,490 KRW per share.
What do the bullish and bearish scenarios say about 326030?
Our models span a range for Sk Biopharmaceuticals Co Ltd: cautious scenario 48,394 KRW, base 83,490 KRW, optimistic 175,949 KRW per share (as of Sep 24, 2026, price 75,900 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sk Biopharmaceuticals Co Ltd (326030)?
Balance-sheet figures for Sk Biopharmaceuticals Co Ltd (as of Sep 24, 2026): return on equity 44.2%, debt of 0.12 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 326030 from its 52-week high?
Sk Biopharmaceuticals Co Ltd trades at 75,900 KRW, about 46% below its 52-week high of 140,700 KRW and at the low of 75,900 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 83,490 KRW is for.
Which stocks are comparable to Sk Biopharmaceuticals Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sk Biopharmaceuticals Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 75,900 KRW, calculated fair value 83,490 KRW (+10%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 326030 calculated?
We run Sk Biopharmaceuticals Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 83,490 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Sk Biopharmaceuticals Co Ltd currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sk Biopharmaceuticals Co Ltd (326030)?
The closing price on Sep 23, 2026 was 75,900 KRW. Our model-based fair value is 83,490 KRW, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sk Biopharmaceuticals Co Ltd right now?
The model range is unusually wide (48,394 KRW to 175,949 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Sk Biopharmaceuticals Co Ltd
How large is the market capitalisation of Sk Biopharmaceuticals Co Ltd (326030)?
The market capitalisation of Sk Biopharmaceuticals Co Ltd is 6.5T KRW (≈ $4.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sk Biopharmaceuticals Co Ltd (326030)?
The price-to-sales ratio of Sk Biopharmaceuticals Co Ltd is 8.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Sk Biopharmaceuticals Co Ltd (326030)?
The net margin of Sk Biopharmaceuticals Co Ltd is 37.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sk Biopharmaceuticals Co Ltd (326030)?
The return on equity (ROE) of Sk Biopharmaceuticals Co Ltd is 44.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sk Biopharmaceuticals Co Ltd (326030)?
On an EBIT basis the return on assets of Sk Biopharmaceuticals Co Ltd is 3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sk Biopharmaceuticals Co Ltd (326030)?
The operating margin of Sk Biopharmaceuticals Co Ltd is 39.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sk Biopharmaceuticals Co Ltd (326030)?
Revenue at Sk Biopharmaceuticals Co Ltd is growing +57.8% versus a year earlier (3y avg +42.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sk Biopharmaceuticals Co Ltd (326030)?
Earnings per share at Sk Biopharmaceuticals Co Ltd are growing +351% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sk Biopharmaceuticals Co Ltd (326030) carry?
The net debt of Sk Biopharmaceuticals Co Ltd is 39.7B KRW (fiscal year 2022, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sk Biopharmaceuticals Co Ltd in the live analysis
One click puts Sk Biopharmaceuticals Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
